SEC Form 4 · accession 0001562180-19-000863
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kyle Lefkoff
Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 7:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2019 | M | 25,000 | $10.47 | A | 47,720 | D | |
| Common StockF1 | Feb 6, 2019 | S | 25,000 | $20.5077 | D | 22,720 | D | |
| Common StockF2,F3,F4 | Feb 6, 2019 | S | 5,000 | $20.8241 | D | 25,000 | I | See footnote |
| Common StockF2,F5,F4 | Feb 6, 2019 | S | 5,000 | $20.8522 | D | 20,000 | I | See footnote |
| Common StockF6 | holding | — | — | — | 15,000 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $10.47 | Feb 6, 2019 | M | 25,000 | D | — | Oct 26, 2027 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1The price reported for these shares is the weighted average sale price of transactions made at prices from $20.50 to $20.58. Details of actual prices for shares sold are available from the Reporting Person upon request.
- F2The sale was made by the Reporting Person as custodian for his son under the Colorado Uniform Gifts to Minors Act.
- F3The price reported for these shares is the weighted average sale price of transactions made at prices from $20.785 to $20.834. Details of actual prices for shares sold are available from the Reporting Person upon request.
- F4Comprised of shares of common stock in trust for the benefit of the Reporting Person's minor children.
- F5The price reported for these shares is the weighted average sale price of transactions made at prices from $20.805 to $20.864. Details of actual prices for shares sold are available from the Reporting Person upon request.
- F6Comprised of common stock held by BV Partners III Profit Sharing account for the benefit of the Reporting Person.
- F7The options vested on October 26, 2018.